Roche and Qualcomm Collaborate to Innovate Remote Patient Monitoring
ROTKREUZ, Switzerland and SAN DIEGO, Jan. 29, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Qualcomm Incorporated (NASDAQ: QCOM) today announced that Qualcomm's subsidiary, Qualcomm Life, Inc., and Roche, a world leader in point-of-care diagnostics, have entered into a strategic collaboration to improve remote monitoring and management of chronic disease patients. Together, the companies aim to advance chronic care management using connected therapy to further improve therapy quality, increase convenience and drive patient engagement in managing their health.
Roche will utilize Qualcomm Life's 2net Platform to seamlessly and securely capture data from a patient's medical devices, beginning with anticoagulation meters, and transmit it to Roche's cloud-based back-end services. The 2net Platform is a secure wireless solution that provides a simple and efficient way to exchange relevant health information between chronic disease patients and their care team or clinic to enable reduced therapy complications and total cost of care.
As health care systems and providers are facing continual pressure to deliver an improved quality of care at a lower cost, patient satisfaction is becoming more important than ever. Connected chronic care management and remote management solutions can enhance patient care, enabling providers to asynchronously communicate with their patients in a high-tech, high-touch model minimizing risk of errors in result reporting. While many remote patient monitoring and management solutions today require patients to communicate results to their health care professionals in manual, time-consuming and non-digitized channels, Qualcomm Life and Roche are working together to deliver an improved process for sharing health information between health care providers and their patients.
"This collaboration marks a significant milestone for Roche as we launch a new generation of point-of-care solutions that enable healthcare professionals to better keep in touch remotely with patients, whenever and wherever they are," says Jeremy Moss, senior vice president, Point of Care at Roche Professional Diagnostics. "By combining Qualcomm Life's leadership in powering connected health solutions with our point-of-care expertise, we are taking an important step forward to realize our connected care strategy; ultimately enabling physicians to improve the overall quality of life for patients."
"We are thrilled to be working with a global industry leader in diagnostics and excited by the positive impact our collaboration with Roche can have on patient empowerment at the point-of-care," said Rick Valencia, senior vice president and general manager, Qualcomm Life, Inc. "Together, Roche and Qualcomm Life are committed to providing tools to patients and their physicians and caregivers that empower greater coordination to improve patient health."
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
About Qualcomm Incorporated
Qualcomm Incorporated (NASDAQ: QCOM) is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm's licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a wholly-owned subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm's engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT. For more than 25 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other. For more information, visit Qualcomm's website, OnQ blog, Twitter and Facebook pages.
Qualcomm and 2net are trademarks of Qualcomm Incorporated, registered in the United States and other countries. 2net is a product of Qualcomm Life, Inc. All Qualcomm Incorporated trademarks are used with permission.
Qualcomm Contacts:
Emily Kilpatrick, Corporate Communications
Phone: 1-858-845-5959
Email: [email protected]
Jamie Eisinger, Qualcomm Life, Inc.
Phone: 1-858-845-1033
Email: [email protected]
Warren Kneeshaw, Investor Relations
Phone: 1-858-658-4813
Email: [email protected]
Roche Contacts:
Jenna Eup, Communications US
Phone: 1-317-521-4477
Email: [email protected]
Daniel Fleiter, Public Relations
Phone: +41 41 798 5990
Email: [email protected]
SOURCE Qualcomm Incorporated
Share this article